COVID-19 Drug Veklury (Remdesivir) Update

May 11, 2022

Beginning April 25, 2022, Veklury (J0248) is an approved benefit for Medicaid and CHIP clients 28 days or older when used in an outpatient setting. Previously, Veklury (remdesivir lyophilized injection) was approved for clients 12 years or older.

On April 25, 2022, the U.S. Food and Drug Administration (FDA) expanded the use of Veklury (remdesivir lyophilized injection) for patients in the outpatient setting. Veklury is indicated for clients meeting all the following:

  • Age 28 days or older
  • Weighing at least 3kg
  • Having mild to moderate COVID-19
  • Are at high risk for progression to severe COVID-19, including hospitalization or death

Resources